CLUSTER filed May 7, 2026 at 20:00 ET
Protagonist Therapeutics CEO Dinesh Patel sold $7.5M worth of stock on May 12, 2026, following a $600K sale by Director Bryan Giraudo on May 8, creating a two-insider sell cluster totaling $8.11M. The sales occurred just 9 days after a massive Q1 earnings beat (revenue $56.4M vs $16.3M consensus, EPS $0.05 vs -$0.65 consensus) driven by milestone payments from ICOTYDE FDA approval and the rusfertide opt-out. While the earnings beat is clearly positive, the CEO's large open-market sale immediately after exercising options at $21.58/share (realizing ~$7.5M profit) is a routine cashless exercise pattern, the stock is up ~364% from the option strike, and the sale represents only ~0.12% of the $6.7B market cap, falling below the 0.5% materiality threshold.